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165 Management of pneumothoraces in cystic ﬁbrosis (CF): a novel
approach using an ambulatory suction device (Thopaz™ system,
Medela Ltd)
C. Addy1, K. Bateman1, N.J. Bell1. 1Bristol Adult Cystic Fibrosis Centre,
University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
Objectives: Pneumothorax in CF is associated with poor prognosis, increased
hospitalisation and deteriorating lung function. Persistent air leaks and delayed lung
expansion lead to slow resolution. We aimed to improve care using ambulatory
suction.
Methods: 3 adults with CF were treated with an ambulatory suction device
(Thopaz™ system) used with intercostal drainage.
Results:
1. Surgical emphysema and persistent air leak in a 22 year old male with pneu-
mothorax led to change from a small bore to large bore drain with suction. Lack
of ambulation and chest pain limited airway clearance. Drain blockage required
repeated ﬂushes. Thopaz system improved airway clearance, reduced pain and
measured air leak. Self ﬂushing mechanism reduced drain blockage, allowing
resolution in 10 days.
2. 19 year old male with end stage lung disease developed a pneumothorax.
Minimal resolution and persistent air leak were seen despite a 12F drain. Patient
declined large bore chest drain and/or suction due to limited ambulation. Surgical
options were considered too high risk. Use of Thopaz system allowed suction use,
maintained ambulation and measured air leak. Successful resolution occurred in
7 days.
3. A 22 year old female presented with ipsiliateral pneumothorax following failed
pleurodesis with persistent air leak and severe dyspnoea. End stage disease
and thrombocytopenia prevented surgical treatment. Pneumothorax resolved with
Thopaz system aiding symptom palliation.
Conclusion: Pneumothorax in CF is complicated by limited surgical options and
slow resolution. Use of an ambulatory suction device improves outcomes and
reduces patient morbidity. We aim to trial this device in future patients.
166 The prevalence and aetiology of pleural effusions and empyema
in patients attending a regional adult CF centre
A.P. Sawant1, C. Etherington1, P. Whitaker1, M. Denton1, G. Fitch1, D. Peckham1.
1St James’s University Hospital, Regional Adult Cystic Fibrosis Unit, Leeds,
United Kingdom
Objectives: To review the prevalence and aetiology of pleural effusions and
empyema in a large cohort of adult patients with Cystic Fibrosis (CF).
Methods: This was a retrospective study looking at all clinical episodes between
01/01/2008 and 01/01/2014. Data for age, weight, lung function, CRP, pleural ﬂuid
analysis, transplant status, intravenous (IV) antibiotics and Read/SNOMED codes
relating to pleural disease were extracted from the unit’s electronic patient care
records.
Results: A total 440 patients [median age 30 (17−70) years, M: 244] were reviewed.
A total of 4,242 courses (67,641 days) of IV antibiotics were administered over the
six year period. Three effusions were reported in 49 post-transplant patients, the
aetiology being related to rejection, post transplant surgery and a spontaneously
resolving lymphocytic effusion. Two cases of loculated empyema were diagnosed
in non transplanted patients chronically colonised with P. aeruginosa (PA). Pleural
Ph, LDH, Protein, Microbiology were 7.23, 1349 iu/L, 47 g/L, culture negative
and 7.019, 1236 iu/L, 49 g/L, PA positive respectively. Both patients had elevated
CRP (96 and 290mg/L) and presented with pyrexia and acute pleuritic chest pain.
One case responded to drain insertion and IV antibiotics, while the other required
installation of intrapleural tissue plasminogen activator (t-PA) and Dnase. Patients
made a full recovery.
Conclusion: Non infective pleural effusions only occurred in post transplant
patients. Despite over 4000 courses of iv antibiotics, there were only two cases of
parapneumonic effusions/empyema. The MIST 2 protocol using (t-PA) and DNase
proved a successful alternative to surgical intervention.
167 Epidemiology and risk factors for CF arthropathy
J. Ro¨hmel1, T. Kallinich1, D. Staab1, C. Schwarz1. 1Charite´ Universita¨tsmedizin
Berlin, Pediatrics Division of Pneumonology and Immunology, Berlin, Germany
Objectives: Extrapulmonary complications play an important role in aging patients
(pts) with CF. From a clinician’s perspective CF related arthropathy (CFA) con-
stitutes a signiﬁcant manifestation of these comorbidities, especially in pts with
advanced CF disease. We conducted this trial in order to assess the prevalence of
CFA and to identify predictors.
Methods: 290 pts currently under treatment in our CF center were analysed in
this trial. Data were collected prospectively and by standardized documentation and
then matched with data from our quality management system.
Results: 43/193 adult pts suffered from relevant arthropathy symptoms of those
16 were diagnosed with rheumatoid arthritis. No Children were affected. 12/16 of
the affected pts were female, their mean age was 42 years, mean BMI 21 and
mean FEV1 predicted was 51%. 75% had a chronic infection with Pseudomonas
aeruginosa 44% had CFRD. 38% were positive for rheumatoid factor. Intermittent
treatment with systemic corticosteroides and NSAID was necessary in all cases. In
three pts methotrexate was used. Two pts were dependent on continous therapy.
Conclusions: Our data suggest that in comparison to the general population
rheumatoid arthritis’ prevalence is eight fold higher in adult pts with CF leading to
a signiﬁcant limitation in quality of life. Pseudomonal colonisation may be a risk-
factor. Conﬁrmation of these ﬁndings in larger cohorts is required. Further research
could feature ultrasound, X-ray, questionaires, screening for surrogat parameters
such as rheumatoid factor and others, elucidation of immunologic mechanisms as
well as the assessment and development of therapeutic strategies.
168 Cystic ﬁbrosis: an ageing condition
M.E. Phitidis1, M. Murthy1, N. Hunt1, G.H. Jones1, J. Fox1, M. Ledson1,
J. Greenwood1, M. Walshaw1. 1Liverpool Heart and Chest Hospital, Respiratory
Medicine, Liverpool, United Kingdom
Objectives: Advances in therapy have improved survival in CF (predicted UK median
now 43.5 years), but better disease awareness means that adult diagnoses are frequent,
potentially skewing the survival rate. We looked at the disease characteristics of our
older (>44 years) patients, and compared adult (AD) diagnoses (58%) with those in
childhood (CD).
Results: 8.45% (24) of 284 patients are >44 years (50% male). All have chronic sputum
infection (96% P. aeruginosa, 13% Burkholderia spp., 25% S. aureus, 13% MRSA,
17% NTM). The mean [SD] FEV1 is 61% predicted [26] (CD 56% [14], AD 64% [29],
P =NS) and the mean BMI 26.5 [4.8] (CD 24.8 [3.3], AD 27.8 [5.2], P =NS). 17% take
oxygen therapy and 8% await lung transplant. Comorbidities include hiatus hernia,
Barrett’s oesophagus, splenomegaly, hypertension, angina, anxiety, constipation and
colonic cancer. Common complications are shown in Table 1 and social status in
Table 2.
Table 1. Common complications
CD AD Total (%) CD AD Total (%)
CF-related diabetes 7 6 13 (54.2) Asthma 1 6 7 (29.2)
Liver disease 4 2 6 (25) GORD 9 13 22 (91.7)
Cholecystectomy 4 0 4 (16.6) Depression 2 2 4 (16.6)
Fatty/atrophic pancreas 9 1 10 (41.7) Arthropathy 2 3 5 (20.8)
ABPA 2 5 7 (29.2) Osteopenia/
osteoporosis
4 5 9 (37.5)
Table 2. Social status
Marital status n (%) Employment status n (%)
Married or long-term relationship 20 (83%) Full time/Housewife 9 (38%)/2 (8%)
Divorced 2 (8%) Part time 3 (13%)
Single 2 (8%) Retired 10 (42%)
Conclusion: The ageing CF population have more CF related complications and in-
creased co-morbidity. Their physical characteristics are independent of age at diagnosis,
reﬂecting the holistic approach offered by adult CF centres where close communication
with other specialities is required to ensure best possible care.
